Immunovia AB (Immunovia) is a diagnostic company that focuses on the early detection of pancreatic cancer through advanced blood-based testing. The company provides clinical diagnostic testing services and works closely with healthcare providers, researchers, and payers to support early cancer detection, clinical validation, and reimbursement pathways. Immunovia’s product is PancreaSure, a next-generation blood test for the early detection of pancreatic ductal adenocarcinoma (PDAC). The company serves high-risk individuals for pancreatic cancer, healthcare professionals, clinical institutions, and the broader oncology diagnostics market. It operates in the life sciences and medical diagnostics sector. Immunovia is headquartered in Lund, Sweden.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Immunovia AB
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Immunovia AB Company Overview
- Immunovia AB Company Snapshot
- Immunovia AB Pipeline Products and Ongoing Clinical Trials Overview
- Immunovia AB - Pipeline Analysis Overview
- Immunovia AB - Key Facts
- Immunovia AB - Major Products and Services
- Immunovia AB Pipeline Products by Development Stage
- Immunovia AB Ongoing Clinical Trials by Trial Status
- Immunovia AB Pipeline Products Overview
- IMMray - Breast Cancer
- IMMray - Breast Cancer Product Overview
- IMMray - NSCLC
- IMMray - NSCLC Product Overview
- IMMray - Prostate Cancer
- IMMray - Prostate Cancer Product Overview
- IMMray PanCan-d
- IMMray PanCan-d Product Overview
- IMMray PanCan-d Clinical Trial
- IMMray PanCan-m Test
- IMMray PanCan-m Test Product Overview
- IMMray Primary Sjogren’s Syndrome Assay
- IMMray Primary Sjogren’s Syndrome Assay Product Overview
- IMMray Rheumatoid Arthritis Assay
- IMMray Rheumatoid Arthritis Assay Product Overview
- IMMray SLE-d Test
- IMMray SLE-d Test Product Overview
- IMMray Systemic Vasculitis Assay
- IMMray Systemic Vasculitis Assay Product Overview
- PancreaSure
- PancreaSure Product Overview
- PancreaSure Clinical Trial
- ProMIS Assay
- ProMIS Assay Product Overview
- Immunovia AB - Key Competitors
- Immunovia AB - Key Employees
- Immunovia AB - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Immunovia AB, Recent Developments
- Jan 23, 2026: Immunovia attends Aktiespararna Life Science
- Jan 19, 2026: Immunovia receives state regulatory approval for PancreaSure in California and initiates commercial rollout
- Dec 22, 2025: Immunovia’s Analytical Validation Study of PancreaSure Published in Diagnostics
- Nov 26, 2025: Immunovia Receives Final Medicare Payment Rate for PancreaSure Test
- Nov 24, 2025: Immunovia: VERIFI Study Published in Current Oncology
- Nov 24, 2025: VERIFI Study Published in Peer-Reviewed Journal Current Oncology
- Oct 27, 2025: Immunovia To Present PancreaSure Clinical Validation Data At ACG Annual Meeting
- Sep 24, 2025: PancreaSure Demonstrates 88% Sensitivity and 98% Specificity in Interim Analysis of Third Validation Study
- Sep 22, 2025: Immunovia Gains Control Over PancreaSure Supply Chain and Reduces Costs Through Licensing Agreement
- Sep 11, 2025: Immunovia Receives Preliminary Payment Determination from CMS for PancreaSure Test
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- Immunovia AB Pipeline Products and Ongoing Clinical Trials Overview
- Immunovia AB Pipeline Products by Equipment Type
- Immunovia AB Pipeline Products by Indication
- Immunovia AB Ongoing Clinical Trials by Trial Status
- Immunovia AB, Key Facts
- Immunovia AB, Major Products and Services
- Immunovia AB Number of Pipeline Products by Development Stage
- Immunovia AB Pipeline Products Summary by Development Stage
- Immunovia AB Ongoing Clinical Trials by Trial Status
- Immunovia AB Ongoing Clinical Trials Summary
- IMMray - Breast Cancer - Product Status
- IMMray - Breast Cancer - Product Description
- IMMray - NSCLC - Product Status
- IMMray - NSCLC - Product Description
- IMMray - Prostate Cancer - Product Status
- IMMray - Prostate Cancer - Product Description
- IMMray PanCan-d - Product Status
- IMMray PanCan-d - Product Description
- IMMray PanCan-d - A Prospective Evaluation of IMMray PanCan-d Biomarker Signature Assay in Subjects with New Onset Diabetes (NOD)
- IMMray PanCan-d - IMMray PanCan-d Utility in Patients with Abdominal Symptoms Attending Secondary Care Centres
- IMMray PanCan-m Test - Product Status
- IMMray PanCan-m Test - Product Description
- IMMray Primary Sjogren’s Syndrome Assay - Product Status
- IMMray Primary Sjogren’s Syndrome Assay - Product Description
- IMMray Rheumatoid Arthritis Assay - Product Status
- IMMray Rheumatoid Arthritis Assay - Product Description
- IMMray SLE-d Test - Product Status
- IMMray SLE-d Test - Product Description
- IMMray Systemic Vasculitis Assay - Product Status
- IMMray Systemic Vasculitis Assay - Product Description
- PancreaSure - Product Status
- PancreaSure - Product Description
- PancreaSure - A Clinical Study to Assess the Effects of Next Generation Pancreatic Cancer Detection Test in the United States
- ProMIS Assay - Product Status
- ProMIS Assay - Product Description
- Immunovia AB, Key Employees
- Immunovia AB, Subsidiaries
- Glossary
- Immunovia AB Pipeline Products by Equipment Type
- Immunovia AB Pipeline Products by Development Stage
- Immunovia AB Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- IDL Diagnostics AB
- Elypta AB
- Biovica International AB
